Alluzience
Ready-to-use BoNT-A neuromodulator in Europe
About This Treatment
Alluzience is a ready-to-use abobotulinumtoxinA product approved in Europe. It is designed to reduce reconstitution steps, preparation time and concentration variability. Approval status must be checked by region.
Mechanism of Action
BoNT-A inhibits acetylcholine release at the neuromuscular junction, temporarily weakening dynamic muscles such as those causing glabellar lines.
Indications
Expected Results
Its clinical positioning builds on abobotulinumtoxinA evidence, with practical advantages from ready-to-use preparation. Onset and duration are explained as BoNT-A class effects.
Clinical Evidence
Risks & Side Effects
Bruising, headache, eyelid ptosis, asymmetry, overcorrection and rare swallowing or breathing symptoms may occur. Unit conversion must not be assumed across brands.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition